Offered through NeuroQuest Inc.

NeuroQuest Inc., a wholly-owned subsidiary of Neurodyn, is a pre-clinical contract research organization that specializes in medicinal chemistry and drug development for neurological conditions. NeuroQuest’s scientists have specific expertise in small molecule drug discovery programs with proven track records of delivering high quality candidates in a timely fashion.  NeuroQuest works closely with its partners to understand their requirements and can synthesize pre-selected compounds or engage in a full lead optimization drug discovery program based on the client’s targets and assays.

NeuroQuest has extensive experience in multiple lead optimization programs in both CNS and non-CNS indications, including:

  • Alzheimer’s Disease, Parkinson’s Disease, ALS
  • Epilepsy, Diabetes
  • Neuropathic Pain
  • Antibacterial, Inflammation, Oncology

Services

Synthesis

  • Synthesis of intermediates from milligram to gram quantities
  • Synthetic route optimization
  • Synthesis of focussed library for in vitro screening

Medicinal Chemistry Group

  • Structure based design, fragment based design and HTS Hit analysis
  • In silico modeling supporting structure based design & SAR (2D/3D QSAR)
  • Synthesis of focussed library, SAR and ADMET optimization
  • IP protection around NCE’s

 Neurology Assays

  • Electrophysiology (DRG patch clamp, state dependency, Nav selectivity)
  • Nav subtype selectivty
  • Transient Receptor Potential Channel (TRP) activity assay (HEK cell)
  • hERG Assay

For inquires about NeuroQuest’s services, visit www.neuroquest.ca

Or contact:

Dr. Denis Kay dgkay@neurodyn.ca

Dr. Alexander McLellan mclellan@neuroquest.ca